查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575739

全球除颤器市场 - 2024-2031

Global Defibrillators Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球除颤器市场在 2023 年达到 128.8 亿美元，预计到 2031 年将达到 222.9 亿美元，2024-2031 年预测期间复合年增长率为 7.1%%。

除颤器是重要的医疗设备，可向心臟提供电击或脉衝以恢復正常心跳，特别是在心臟骤停（也称为心臟骤停 (SCA)）的情况下。当心律因心室颤动或无脉性心室心搏过速等情况而停止时，除颤器可以帮助心臟重新启动。除非立即进行心肺復苏术 (CPR) 和使用除颤器治疗，否则心臟骤停是致命的。

除颤器透过向心肌提供电击来发挥作用。这种电击使心臟组织的很大一部分去极化，有效地破坏导致心律不整的紊乱电活动。主要目的是重置心臟的电系统，使其恢復正常节律。除颤器针对的主要心律不整是心室颤动和无脉性心室心搏过速。

市场动态：

司机

心血管疾病 (CVD) 盛行率的增加和技术进步

全球除颤器市场的需求是由多种因素所驱动的。关键因素之一是心血管疾病（CVD）盛行率的增加和技术的进步。心血管疾病（CVD）是全世界最主要的死因。冠状动脉疾病和心臟衰竭等心血管疾病（CVD）发生率的增加是推动去颤器市场成长的主要因素。

根据世界卫生组织 2024 年 5 月的资料，心血管疾病（CVD）是欧洲地区残疾和过早死亡的主要原因，占年度死亡人数的 42.5% 以上，相当于每天约有 10,000 人死亡。根据世界卫生组织/欧洲的报告，该地区男性死于心血管疾病的可能性是女性的近 2.5 倍。

此外，还存在明显的地理差异；东欧和中亚因心血管疾病而年轻（30 岁至 69 岁）死亡的可能性几乎是西欧的五倍。由于心血管疾病 (CVD) 是欧洲死亡和残疾的首要原因，因此迫切需要在心臟紧急情况下立即进行除颤。

此外，除颤器技术的持续创新正在显着提高设备效率和使用者友善性，这对于改善心臟紧急情况下的患者治疗效果至关重要。现代除颤器，特别是植入式心臟復律去颤器(ICD) 和自动体外除颤器(AED)，现在融入了先进的功能，有助于更好地监测和治疗有心臟骤停风险的患者。

此外，意识计划和推出创新产品等政府措施正在推动该市场的成长。例如，2023 年 7 月，北方邦政府宣布了一项重大倡议，透过在所有政府大楼、商场和其他公共场所（包括北方邦秘书处）安装自动体外心臟去颤器 (AED) 来改善公共卫生。该倡议旨在为发生心臟骤停的个人提供必要的急救。

此外，2023年1月，迈瑞宣布推出新一代BeneHeart系列除颤器，特别是BeneHeart D60和D30型号。这些先进的设备旨在透过提供卓越的可靠性、全面的诊断功能和监测工具来提高復苏标准。这些除颤器的推出旨在为院内和院前紧急情况提供完整的品质改进解决方案。

限制

产品召回、设备成本高、与设备使用相关的担忧、缺乏熟练专业人员以及监管挑战等因素预计将阻碍市场发展。

细分市场分析

全球除颤器市场根据产品类型、年龄层、最终用户和地区进行细分。

体外去颤器部分约占全球除颤器市场份额的73.3%

预计体外除颤器领域将在预测期内占据最大的市场份额。体外心臟去颤器是一种医疗设备，旨在对心臟进行电击，以在危及生命的心律不整（例如心室颤动和无脉性室性心动过速）期间恢復其正常节律。

这些设备对于治疗心臟骤停 (SCA) 至关重要，这种情况是指心臟意外停止有效运作。体外去颤器包括手动体外心臟去颤器、穿戴式心臟復律去颤器和自动体外去颤器（AED）。

此外，该地区的主要参与者、产品发布和宣传计划有助于推动该细分市场的市场成长。例如，2024 年 3 月，全球领先的医疗科技公司 Stryker 参加了在印度加尔各答 ITC 皇家孟加拉会议中心举行的 Criticare 全国会议。在本次活动中，史赛克推出并展示了两款创新产品：LIFEPAK CR2自动体外心臟去颤器（AED）和专为紧急患者疏散设计的疏散椅。

LIFEPAK CR2 是一款创新除颤器，可让救援人员在心臟骤停 (SCA) 紧急情况下提供高品质的心肺復苏术并立即提供电击。这种革命性的设备旨在增强救援人员为心臟骤停的受害者提供救生护理的能力。

同样，2024 年 1 月，Speedy Hire 启动了一项救生计划，为其遍布英国的工程车配备自动体外心臟去颤器 (AED)。此次部署首先安装 18 个除颤器，并计划将其扩展到 Speedy Hire 工程师的货车中的 300 多个便携式设备。该倡议旨在解决英国每年有超过 30,000 人发生院外心臟骤停、存活率不足 10% 的令人担忧的统计数据。 Speedy Hire 旨在透过在货车中提供 AED 来增强紧急情况下的即时回应能力，确保在需要时随时提供协助。

市场地理分析

北美约占全球除颤器市场份额的43.7%

由于心臟病、心臟衰竭和冠心病等心血管疾病的发病率不断增加，北美地区预计将在预测期内占据最大的市场份额，这是北美市场成长的重要推动力。

心臟病是美国男性和女性死亡的主要原因。 2022 年，心血管疾病夺走了 702,880 人的生命，这意味着每 33 秒就有 1 人死亡，约占全国每 5 人死亡人数中就有 1 人死于心血管疾病。

此外，意识宣传活动和政府措施提高了自动体外心臟去颤器 (AED) 的重要性，推动了北美市场的成长。美国许多州已颁布法律，强制在特定公共场所安装 AED，包括高速公路休息区、政府大楼、公共安全车辆、饭店、紧急护理中心和零售健康诊所。

此外，在该地区，大量关键参与者的存在、先进的医疗基础设施、技术进步以及产品发布和批准将推动该市场的成长。例如，2023 年10 月，美敦力(Medtronic) 的Aurora 血管外植入式心臟復律去颤器(EV-ICD) 获得FDA 批准，这是一种创新设备，旨在治疗心律异常和预防心臟骤停(SCA)。这种创新的除颤器代表了心臟护理技术的重大进步。

此外，2023 年 1 月，Avive Solutions 的创新 Avive AED（一种独特的自动体外心臟去颤器 (AED)）获得了美国食品药物管理局 (FDA) 的上市前批准 (PMA)。此次批准标誌着心臟急救技术的重大进步。

Avive AED 是一款开创性设备，它将蜂窝、WiFi、GPS 和蓝牙连接整合到紧凑的手持式设备中。这套连接功能为 Avive 突破性的 REALConnect 技术提供支持，该技术旨在透过与 RapidSOS 的合作与 911 急诊中心无缝连接。因此，该设备可以将关键事件资料即时传输给 911 调度员、紧急医疗服务 (EMS) 和医疗保健专业人员，从而增强态势感知并优化紧急应变工作。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 心血管疾病 (CVD) 盛行率的增加和技术进步
    • 限制
      • 产品召回
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：依产品类型

  • 植入式心臟復律去颤器 (ICD)
    • 经静脉植入式心臟復律去颤器 (T-ICD)
    • 皮下植入式心臟復律去颤器 (S-ICD)
    • 心臟再同步治疗去颤器 (CRT-D)
  • 体外去颤器
    • 手动体外心臟去颤器
    • 穿戴式心臟復律去颤器
    • 自动体外去颤器 (AED)
      • 半自动 AED
      • 全自动 AED

第 7 章：按年龄组

  • 儿科
  • 成年人

第 8 章：最终用户

  • 医院
  • 心臟中心
  • 家庭护理设置
  • 其他的

第 9 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Medtronic
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Boston Scientific Corporation
  • Abbott
  • Koninklijke Philips NV
  • Stryker
  • NIHON KOHDEN CORPORATION
  • Mindray Medical India Pvt. Ltd.
  • MicroPort Scientific Corporation.
  • ZOLL Medical Corporation
  • Biotronik (*LIST NOT EXHAUSTIVE)

第 12 章：附录

简介目录
Product Code: MD780

Report Overview

The Global Defibrillators Market reached US$ 12.88 billion in 2023 and is expected to reach US$ 22.29 billion by 2031 growing with a CAGR of 7.1%% during the forecast period 2024-2031.

Defibrillators are critical medical devices that deliver an electric shock or pulse to the heart to restore a normal heartbeat, particularly in cases of cardiac arrest, also known as sudden cardiac arrest (SCA). When the heart's rhythm ceases due to conditions such as ventricular fibrillation or pulseless ventricular tachycardia, a defibrillator can help restart the heart. A sudden cardiac arrest is fatal unless treated immediately with cardiopulmonary resuscitation (CPR) and the use of a defibrillator.

Defibrillators function by delivering an electric shock to the heart muscle. This shock depolarizes a significant portion of the heart tissue, effectively disrupting the disordered electrical activity that leads to arrhythmias. The primary aim is to reset the heart's electrical system, enabling it to regain a normal rhythm. The main arrhythmias that defibrillators target are ventricular fibrillation and pulseless ventricular tachycardia.

Market Dynamics: Drivers

Increasing prevalence of cardiovascular diseases (CVDs) and technological advancements

The demand for the global defibrillators market is driven by multiple factors. One of the key factors is the increasing prevalence of cardiovascular diseases (CVDs) and technological advancements. Cardiovascular diseases (CVDs) are the foremost cause of death worldwide. The increasing occurrence of cardiovascular diseases (CVDs), such as coronary artery disease and heart failure, is a major factor driving the growth of the defibrillator market.

According to the WHO data in May 2024, Cardiovascular diseases (CVDs) are the primary cause of disability and premature death in the European Region, accounting for over 42.5% of all annual deaths, which translates to approximately 10,000 fatalities each day. As per the report from WHO/Europe, men in this region are nearly 2.5 times more likely to succumb to CVD compared to women.

Additionally, there is a marked geographic disparity; the likelihood of dying young (between the ages of 30 and 69) from a CVD is almost five times greater in Eastern Europe and Central Asia than in Western Europe. With cardiovascular diseases (CVDs) being the foremost cause of death and disability in Europe, there is an urgent requirement for immediate access to defibrillation during cardiac emergencies.

Moreover, continuous innovations in defibrillator technology are significantly enhancing device efficiency and user-friendliness, which is crucial for improving patient outcomes during cardiac emergencies. Modern defibrillators, particularly Implantable Cardioverter Defibrillators (ICDs) and Automated External Defibrillators (AEDs), now incorporate advanced features that facilitate better monitoring and treatment of patients at risk of sudden cardiac arrest.

In addition, government initiatives such as awareness programs and the introduction of innovative product launches are driving this market growth. For instance, in July 2023, the Uttar Pradesh government announced a significant initiative to improve public health by installing Automated External Defibrillators (AEDs) in all government buildings, malls, and other public places, including the Uttar Pradesh Secretariat. This initiative aims to provide essential first aid to individuals experiencing cardiac arrest.

Also, in January 2023, Mindray announced the launch of its next-generation BeneHeart series defibrillators, specifically the BeneHeart D60 and D30 models. These advanced devices are designed to elevate the standards of resuscitation by offering superior reliability, comprehensive diagnostic capabilities, and monitoring tools. The introduction of these defibrillators aims to provide a complete quality improvement solution for both in-hospital and pre-hospital emergencies.

Restraints

Factors such as product recalls, the high cost of devices, concerns associated with the usage of devices, lack of skilled professionals, and regulatory challenges are expected to hamper the market.

Market Segment Analysis

The global defibrillators market is segmented based on product type, age group, end-user, and region.

The external defibrillators segment accounted for approximately 73.3% of the global defibrillators market share

The external defibrillators segment is expected to hold the largest market share over the forecast period. External defibrillators are medical devices designed to deliver an electric shock to the heart to restore its normal rhythm during life-threatening cardiac arrhythmias, such as ventricular fibrillation and pulseless ventricular tachycardia.

These devices are essential for treating sudden cardiac arrest (SCA), a condition where the heart unexpectedly stops functioning effectively. External defibrillators include manual external defibrillators, wearable cardioverter defibrillators, and automated external defibrillators (AEDs).

Moreover, key players in the region, product launches, and awareness programs help to propel this segment's growth in the market. For instance, in March 2024, Stryker, a leading global medical technology company, participated in the Criticare National Conference, which took place at the ITC Royal Bengal in Kolkata, India. During this event, Stryker launched and showcased two innovative products: LIFEPAK CR2 automated external defibrillator (AED) and the Evacuation Chair designed for emergency patient evacuation.

The LIFEPAK CR2 is an innovative defibrillator that empowers rescuers to deliver high-quality CPR and provide immediate shocks during sudden cardiac arrest (SCA) emergencies. This revolutionary device is designed to enhance the ability of rescuers to provide life-saving care to victims of sudden cardiac arrest.

Similarly, in January 2024, Speedy Hire initiated a life-saving program to equip its engineer vans across the UK with Automated External Defibrillators (AEDs). The rollout starts with the installation of 18 defibrillators, with plans to expand this to over 300 portable devices in the vans of Speedy Hire's engineers. This initiative aims to address the concerning statistic that more than 30,000 individuals in the UK suffer from out-of-hospital cardiac arrests annually, with less than 10% surviving. By providing AEDs in their vans, Speedy Hire intends to enhance immediate response capabilities during emergencies, ensuring that help is readily available when needed.

Market Geographical Analysis

North America accounted for approximately 43.7% of the global defibrillators market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing occurrence of cardiovascular diseases, such as heart attack, heart failure, and coronary heart disease, which is a significant driver of market growth in North America.

Heart disease is the primary cause of mortality for men, and women, in the United States. In 2022, cardiovascular disease claimed the lives of 702,880 people, which translates to one death every 33 seconds and accounts for approximately one out of every five deaths nationwide.

Moreover, awareness campaigns and government initiatives propel the significance of automated external defibrillators (AEDs) fueling market growth in North America. Numerous states in the U.S. have enacted laws mandating the installation of AEDs in specific public locations, including highway rest areas, government buildings, public safety vehicles, hotels, urgent care centers, and retail health clinics.

Additionally, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, technological advancements, and product launches & approvals would propel this Market growth. For instance, in October 2023, Medtronic received FDA approval for its Aurora Extravascular Implantable Cardioverter Defibrillator (EV-ICD), an innovative device designed to treat abnormal heart rhythms and prevent sudden cardiac arrest (SCA). This innovative defibrillator represents a significant advancement in cardiac care technology.

Also, in January 2023, Avive Solutions received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) for its innovative Avive AED, a unique Automated External Defibrillator (AED). This approval signifies a major advancement in cardiac emergency response technology.

The Avive AED is a pioneering device that integrates cellular, WiFi, GPS, and Bluetooth connectivity into a compact, handheld format. This suite of connectivity features powers Avive's groundbreaking REALConnect Technology, which is designed to seamlessly connect with 911 emergency centers through a collaboration with RapidSOS. As a result, the device can transmit critical incident data to 911 dispatchers, emergency medical services (EMS), and healthcare professionals in real-time, enhancing situational awareness and optimizing emergency response efforts.

Market Segmentation

By Product Type

Implantable Cardioverter Defibrillators (ICDs)

Transvenous Implantable Cardioverter Defibrillators (T-ICDs)

Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs)

Cardiac Resynchronization Therapy Defibrillators (CRT-D)

External Defibrillators

Manual External Defibrillators

Wearable Cardioverter Defibrillators

Automated External Defibrillators (AEDs)

Semi-Automated AEDs

Fully Automated AEDs

By Age Group

Pediatrics

Adults

By End-User

Hospitals

Cardiac Centers

Homecare Settings

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the defibrillators market include Medtronic, Boston Scientific Corporation, Abbott, Koninklijke Philips N.V., Stryker, NIHON KOHDEN CORPORATION, Mindray Medical India Pvt. Ltd., MicroPort Scientific Corporation., ZOLL Medical Corporation, and Biotronik among others.

Key Developments

In June 2024, the launch of the first-ever Hato Hone St John branded defibrillators represents a significant advancement in emergency cardiac care technology. These new Automated External Defibrillators (AEDs), developed in partnership with medical technology manufacturer ViVest, are designed to deliver a shock to a patient in as little as seven seconds, which is crucial during sudden cardiac arrest (SCA) situations.

In May 2024, London Hearts, a leading defibrillator charity in the UK, announced the launch of a new scheme aimed at making defibrillators more accessible and affordable to communities across the country. The charity provides funding through grants to help organizations and communities acquire these life-saving devices. The scheme is a significant step towards making defibrillators more affordable and widely available throughout the UK.

In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICDs) and INVICTA defibrillation lead in Japan. Both devices are MRI conditional at 1.5T and 3T when implanted as a system. This advanced technology ensures low current consumption, leading to a predicted lifespan that is up to 8 years longer than other ICD devices. Additionally, the ULYS incorporates the PARAD+ arrhythmia discrimination algorithm, which has been clinically proven to have the lowest rate of inappropriate shocks.

Why Purchase the Report?

To visualize the global defibrillators market segmentation based on product type, age group, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the defibrillators market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global defibrillators market report would provide approximately 62 tables, 51 figures, and 183 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Cardiovascular Diseases (CVDs) And Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Product Recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Implantable Cardioverter Defibrillators (ICDs)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Transvenous Implantable Cardioverter Defibrillators (T-ICDs)
    • 6.2.4. Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs)
    • 6.2.5. Cardiac Resynchronization Therapy Defibrillators (CRT-D)
  • 6.3. External Defibrillators
    • 6.3.1. Manual External Defibrillators
    • 6.3.2. Wearable Cardioverter Defibrillators
    • 6.3.3. Automated External Defibrillators (AEDs)
      • 6.3.3.1. Semi-Automated AEDs
      • 6.3.3.2. Fully Automated AEDs

7. By Age Group

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 7.1.2. Market Attractiveness Index, By Age Group
  • 7.2. Pediatrics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adults

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiac Centers
  • 8.4. Homecare Settings
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Medtronic*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Boston Scientific Corporation
  • 11.3. Abbott
  • 11.4. Koninklijke Philips N.V.
  • 11.5. Stryker
  • 11.6. NIHON KOHDEN CORPORATION
  • 11.7. Mindray Medical India Pvt. Ltd.
  • 11.8. MicroPort Scientific Corporation.
  • 11.9. ZOLL Medical Corporation
  • 11.10. Biotronik (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us